Lv1
40 积分 2023-11-03 加入
Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab
14小时前
已完结
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
16天前
已完结
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
19天前
已完结
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial
21天前
已完结
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
22天前
已完结
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
22天前
已完结
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
22天前
已完结
Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
22天前
已完结
Silk fibroin as a potential candidate for bone tissue engineering applications
2个月前
已完结
Silk-based biomaterials
2个月前
已完结
皖公网安备34019202002308
